Read More

Ligand Pharmaceuticals Sees 2023 Total Core Revenue Of $118M-$122M; Sees Adjusted Diluted EPS Of $3.10-$3.30 In 2023; Ligand Estimates That At End Of 2022 It Will Have $150M Of Cash And Investments Available To Fund Its M&A Initiatives

Executive Management Reviewed Business Model and Growth Drivers Following the Successful Spin-Off of OmniAb, Introduced 2023 Financial Guidance Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that

LGND